Designing appropriate non-clinical safety studies requires thoughtful, and sometimes experimental, consideration of the delivery methodology for the therapeutic. The choice of formulation affects drug release and absorption and has a direct impact on the pharmacokinetic profile and associated response of the model system. The formulation should be compatible with the study design, species, and test article.
During the discovery phase, the formulation needs to only sufficiently deliver the therapeutic to support proof-of-concept and lead target identification studies. The robustness of these formulations with respect to accuracy, homogeneity, repeatability and stability, is not typically considered until regulated safety data is being generated. For regulated preclinical work, formulations need to perform reliably and consistently while maximising exposure in the animal model to the therapeutic. To demonstrate that the formulations are robust, accurate analytical methods need to be developed and validated in accordance with regulatory expectations. Reference is usually made to the AAPS whitepaper1 for guidance on the typical analytical activities required to support GLP toxicology studies.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
In generating investigational new drug (IND)-enabling data, three different formulations are commonly required for small molecules: one for the general toxicology safety evaluation studies; one used in the in vitro genetic toxicology assays (GeneTox); and one for use in the human ether-a-go-go (hERG) assay. The GeneTox formulation typically consists of a neat solvent, most commonly DMSO or water, and needs to span a wide range of concentrations (typically 0.001 to 100mg/mL). The hERG assay requires the formulation buffer to sustain the integrity and biological activity of the hERG patch clamp and is typically limited to physiological salt solutions that may contain low levels of organic solvent. The GeneTox and hERG formulations often require time to establish solubility limits and compatibility effects to ensure proper exposure. Such formulations fit a specific need and options are limited in the vehicle composition.
The analytical methodology for each formulation requires validation, and the stability of each formulation needs to be established. As a minimum, stability data must cover the duration between formulation preparation and time of dosing. Additional stability data is desirable to allow larger batch preparations, which leads to reduced waste, cost and technical resources; this also allows preparations to be scheduled and analysed well in advance of dosing.
To assist in screening vehicles for animal studies, pre-formulation studies focus on the physicochemical properties of the drug substance and existing data on drug solubility, hydrophobicity, salt form, crystal form, and physical stability. The sponsor or a contract manufacturing site typically does this work and the results are used to identify the optimal salt and polymorphic form to ensure that the test article will perform as intended between batches and upon storage. These findings help support the development of the clinical formulation, but the information is imminently beneficial to the non-clinical formulation, if available.
Simplifying formulation activities
Good pre-formulation data can help simplify formulation activities by identifying the optimal solvent, pH, or additive, and by providing the physical form of a drug substance that will more consistently formulate at the high concentrations needed to support the IND-enabling drug safety studies. If the salt form planned for the clinic has not been defined and the high dose in non– clinical studies is a suspension, there is the risk that a change in salt form could dramatically impact the bioavailability and ultimately the safety margin established in the preclinical drug safety studies.
Guidances2,3 provide a couple of options to meet safety margins that would permit continued development in the clinic. Common approaches for small molecules are a 50-fold margin of exposure or a limit dose of 1,000mg/kg/day. Alternatively, an appropriate 10-fold exposure multiple for biologics is targeted. Many sponsors intend to use the same vehicle used in discovery for the IND-enabling work, only to find that the high dose is either insoluble, or too viscous to dose upon scale-up. Alternatively, the lowest dose may result in less exposure to the therapeutic than expected due to handling, materials or equipment losses, and the problem is discovered only upon implementing analytical methods to support the GLP safety assessments.
To avoid these situations and ensure efficient execution of regulated preclinical studies, one should plan to perform an analytical evaluation of test batches at sufficient scale to get an accurate read on the ‘dosability’ of the formulation, while also ensuring that preparations are accurate. If drug substance supply is limited, an intermediate scale preparation of 5-10mL is often sufficient, although smaller volumes may not always provide a good read on the physical properties of the formulation on scale-up, or allow for reliable sampling and accurate testing.
In the non-clinical space where the purpose is to achieve high exposure, oral vehicles can differ from those planned for the clinic. Consider that most orally administered therapeutics are dosed as capsules or tablets whereas most non-clinical studies use hundreds of animals that would require thousands of capsules to be filled or tablets to be prepared. Clearly, a solution dose is the most expeditious approach for non-clinical studies. For parenteral and topical formulations, the non-clinical studies should use the intended clinical formulation; however, selection of the proper form of the drug substance as aforementioned is even more crucial to achieving concentrations that provide a sufficient safety margin over the clinical dose.
Formulating biologics
Biologics are formulated as stock solutions or as lyophilised powders, subsequently diluted to the desired concentration and administered parenterally. For protein therapeutics, there are significant challenges in developing them as stock solutions, as the shelf life may need to be longer than two years to cover the duration of the studies. The design of the formulation matrix is a primary focus and the sponsor or delegated contract manufacturing laboratory extensively tests to confirm characterisation and stability when developing the stocks. Regardless, if the biologic is a stock solution or in powder form, the dosing concentration and stability needs to be tested as per the GLP requirements.
Concentration analyses may be assessed by simple 280nm absorbance (A280) measurements for proteins or A260 for nucleic acid therapies; however, these tests alone are not generally acceptable to regulatory agencies to support the stability of the diluted mixtures. The properties of the molecule often dictate the appropriate platform used to confirm stability. Sponsor and formulators should have accumulated information on the most likely degradation pathway for their particular therapeutic agent in the development of the stock matrix, and can then assess the ability of the method to monitor stability. For example, when the aggregate formation is a primary concern, size exclusion chromatography can be used to support the stability of large molecules as it can detect and monitor aggregates and fragments that form upon storage. Alternatively, if instability results in the loss of an amino or nucleic acid unit, a conventional HPLC analysis monitoring the resulting degradation products may be more appropriate.
In developing the non-clinical formulation, it is critical that excipients are well tolerated and safe, regardless of the route of administration. Historical data is used to aid non-clinical vehicle selection, as the compatibility with the species are known, and effects would be known if they were to interfere with a given indication. Research into the safety and compatibility of solvents, excipients, and additives in multiple species, routes of administration and dosing duration is continually ongoing.
The review by Gad et al4 provides a variety of options to consider in selecting the vehicle components that can meet the needs of the programme. As mentioned therein, the test system, route of administration, target indication and species often direct the formulation of the test article and dictate boundary conditions around excipients, pH, dose volume, and concentrations. The limits and permissible ranges of each parameter can vary between species and route of administration, most specifically with parenteral dosage forms. Values outside the typical ranges are permissible in certain situations and governed by the testing facilities’ institutional animal care and use committee (IACUC).
An initial screen
As different excipients and vehicle combinations are evaluated, visual assessment of the physical properties is a good initial screen. From there, the upper limit of concentration, osmolality, pH, density and homogeneity can be assessed for compatibility with the planned test system. When multiple vehicles seem equally viable based on physicochemical assessments or when comparing routes of administration, additional discovery PK studies can generate data on the formulation or delivery system that provides the desired exposure. Results from such studies can benefit both clinical and non-clinical general toxicology formulation selections.
Prior to preparing formulations for a regulated study, test article characterisation is generally required. The GLP requirements state that the identity, strength, purity, composition and other characteristics that define the test or control article must be determined and documented for each batch. The sponsor, or a delegated laboratory or contract manufacturer, is typically responsible for the test article characterisation. Furthermore, stability of the bulk material also needs to be determined either prior to study initiation or concomitantly with the study, provided periodic analysis of each batch is planned and performed.
The sponsor typically performs the stability assessment or delegates this work to a contract analytical laboratory; however, if the testing facility has sufficient analytical capabilities, it is possible to perform bulk stability assessment as part of the safety study. A certificate of analysis, statement of testing, or other appropriate documentation to support the integrity and stability of the test article should be provided to the CRO performing the nonclinical study. Clear documentation or communication on sample storage conditions and the number of known and supported freeze/thaw cycles as applicable either prior to or along with the shipment are also required.
International Conference on Harmonisation, Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3(R2). www. fda.gov/downloads/drugs/ guidances/ucm073246.pdf
International Conference on Harmonisation, Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6(R1). www. fda.gov/downloads/Drugs/…/ Guidances/UCM194490.pdf
Gad SC, Spainhour CB, Shoemake C, Stackhouse Pallman DR, Stricker-Krongrad A, Downing PA, Seals RE, Eagle LA, Polhamus K, Daly J. Tolerable Levels of Nonclinical Vehicles and Formulations Used in Studies by Multiple Routes in Multiple Species With Notes on Methods to Improve Utility. Int J Toxicol. 2016;35(2):95-178. DOI: 10.1177/1091581815622442
Biography
DR DAVID KELLER is Associate Director, Bioanalytical/Analytical Sciences at MPI Research. He has over 15 years’ experience as an analytical chemist in academia, CMO, CRO, and in large pharmaceutical environments. Dr Keller has led analytical efforts in support of GMP manufacture for numerous APIs and has overseen development and validation of hundreds of dose formulation methods.
The rest of this article is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
bi-monthly issues in print and/or digital format
case studies, whitepapers, webinars and industry-leading content
breaking news and features
our extensive online archive of thousands of articles and years of past issues
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.